Relapsing polychondritis (RP) is a rare autoimmune disease that affects cartilaginous tissues and proteoglycan-rich organs. Around 30% of cases have coexisting autoimmune inflammatory diseases. Palmoplantar pustulosis (PPP) is extremely uncommon in RP. We report a case of resistant RP, complicated with PPP. A 36-year-old female presented with fever, nose and earlobe chondritis, and symmetric arthritis. Infectious and connective tissue diseases were ruled out. The RP diagnosis was made, and she was treated with corticosteroids and methotrexate. Three years later, she experienced acute dyspnea due to tracheobronchial chondritis, and she was placed on induction treatment with 6 cyclophosphamide pulses, accompanied by maintenance therapy with mycophenolate mofetil (MMF). After 4 years, she presented with scleritis and panuveitis. The MMF was discontinued, and she was treated with tocilizumab (TCZ) 162 mg/week. Four months after the initiation of TCZ, the patient experienced erythematous papules and pustules on both palms and soles, suggestive of PPP. She received oral corticosteroids in addition to TCZ, with complete regression of symptoms.
BicaBERGde SouzaAWSPereiraIA.Unveiling the clinical spectrum of relapsing polychondritis: insights into its pathogenesis, novel monogenic causes, and therapeutic strategies. Adv Rheumatol. 2024;64:29.
2.
BorgiaFGiuffridaRGuarneriFCannavòS.Relapsing polychondritis: an updated review. Biomedicines. 2018;6:84.
3.
FoidartJMAbeSMartinGM, et al. Antibodies to type II collagen in relapsing polychondritis. N Engl J Med. 1978;299:1203-1207.
4.
CantariniLVitaleABriziMG, et al. Diagnosis and classification of relapsing polychondritis. J Autoimmun. 2014;48-49:53-59.
5.
McAdamLPO’HanlanMABluestoneRPearsonCM.Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore). 1976;55:193-215.
6.
DamianiJMLevineHL.Relapsing polychondritis-report of ten cases. Laryngoscope. 1979;89:929-946.
7.
FarhatRClavelGVilleneuveD, et al. Sustained remission with tocilizumab in refractory relapsing polychondritis with ocular involvement: a case series. Ocul Immunol Inflamm. 2020;29:9-13.
8.
TbiniMRiahiIBen AmmarCBen SalahM.Relapsing polychondritis. Med Clin (Barc). 2025;165:106985.
9.
IsaakBLLiesegangTJMichetCJJr.Ocular and systemic findings in relapsing polychondritis. Ophthalmology. 1986;93:681-689.
10.
HorváthAPállNMolnárK, et al. A nationwide study of the epidemiology of relapsing polychondritis. Clin Epidemiol. 2016;8:211-230.
11.
HazraNDreganACharltonJGullifordMCD’CruzDP.Incidence and mortality of relapsing polychondritis in the UK: a population-based cohort study. Rheumatology (Oxford). 2015;54:2181-2187.
FrancèsCEl RassiRLaporteJLRybojadMPapoTPietteJC.Dermatologic manifestations of relapsing polychondritis. Medicine. 2001;80:173-179.
14.
HebbarMDecoulxMFenauxP.Polychondrite chronique atrophiante et syndrome myélodysplasique. À propos de deux observations. La Revue De Médecine Interne. 1991;12:S475.
15.
PàmiesAFerràsPBellaubí-PallarésNGiménezTRaventósAColobranR.VEXAS syndrome: relapsing polychondritis and myelodysplastic syndrome with associated immunoglobulin A vasculitis. Rheumatology (Oxford). 2021;61:e69-e71.
16.
FerradaMASikoraKALuoY, et al. Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS. Arthritis Rheumatol. 2021;73:1886-1895.
17.
TsuchidaNKunishitaYUchiyamaY, et al. Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis. Ann Rheum Dis. 2021;80:1057-1061.
18.
KhitriMYGuedonAFGeorgin-LavialleS, et al. Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients. RMD Open. 2022;8:e002255.
19.
YangCLBrinckmannJRuiHF, et al. Autoantibodies to cartilage collagens in relapsing polychondritis. Arch Dermatol Res. 1993;285:245-249.
20.
LangBRothenfusserALanchburyJS, et al. Susceptibility to relapsing polychondritis is associated with HLA-DR4. Arthritis Rheum. 1993;36:660-664.
21.
ZeunerMStraubRHRauhGAlbertEDSchölmerichJLangB.Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients. J Rheumatol. 1997;24:96-101.
22.
ArnaudLCostedoat-ChalumeauNMathianA, et al. French practical guidelines for the diagnosis and management of relapsing polychondritis. Rev Med Interne. 2023;44:282-294.
23.
PadoanRCampanielloDIorioLDoriaASchiavonF.Biologic therapy in relapsing polychondritis: navigating between options. Expert Opin Biol Ther. 2022;22:661-671.
24.
LerouxGCostedoat-ChalumeauNBrihayeB, et al. Treatment of relapsing polychondritis with rituximab: a retrospective study of nine patients. Arthritis Rheum. 2009;61:577-582.
25.
NeychevaSKamburovaA.IL-17 inhibitor secukinumab achieves remission in relapsing polychondritis: a case report. Am J Case Rep. 2025;26:e946916.
26.
AliSBHughesTSmithA.Anakinra in relapsing polychondritis: a case report and review of the literature. Immunotherapy. 2025;17:5-9.
27.
YangRRheeRLQuinnKA, et al. Clinical manifestations and treatment in patients with relapsing polychondritis: a multicenter observational cohort study. ACR Open Rheumatol. 2025;7:e70027.
28.
ChandranVShenHPollockRA, et al. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis. J Rheumatol. 2013;40:866-871.
29.
SatoTYamanoYTomaruU, et al. Serum level of soluble triggering receptor expressed on myeloid cells-1 as a biomarker of disease activity in relapsing polychondritis. Mod Rheumatol. 2014;24:129-136.
30.
PuttisriTThaiwatS.Concurrence of psoriasis and relapsing polychondritis: a case report. Thai J Dermatol. 2021;37:173-177.
31.
TeruiTMurakamiMOkuboYHayamaKFujitaH.Palmoplantar pustulosis as an immune-mediated inflammatory disease with a possible relevance of Th17 cell plasticity: a narrative review. Dermatol Ther. 2025;15:797-810.
32.
MurakamiMHagforsenEMorhennVIshida-YamamotoAIizukaH. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol. 2011;20:845-847.
33.
SzantoELinseU.Arthropathy associated with palmoplantar pustulosis. Clin Rheumatol. 1991;10:130-135.
34.
AkiyamaTSeishimaMWatanabeHNakataniAMoriSKitajimaY.The relationships of onset and exacerbation of pustulosis palmaris et plantaris to smoking and focal infections. J Dermatol. 1995;22:930-934.
35.
KounoMAkiyamaYMinabeM, et al. Dysbiosis of oral microbiota in palmoplantar pustulosis patients. J Dermatol Sci. 2019;93:67-69.
36.
ShmidtEWetterDAFergusonSBPittelkowMR.Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the mayo clinic experience, 1998 to 2010. J Am Acad Dermatol. 2012;67:e179-e185.
37.
Villalobos-SánchezLLarena-GrijalbaCAlía-JiménezASifuentes-GiraldoWA.Pustulosis palmoplantar inducida por certolizumab pegol: presentación de un caso y revisión de la literatura. Reumatología Clínica. 2019;15:e163-e165.
38.
BaeJMEunSHKimKJ.Palmoplantar pustulosis secondary to anti-tumor necrosis factor therapy in a patient with ankylosing spondylitis. Korean J Intern Med. 2019;35:254-255.
39.
AndradePLopesSGasparRNunesAMaginaSMacedoG.Anti-tumor necrosis factor-α-induced dermatological complications in a large cohort of inflammatory bowel disease patients. Dig Dis Sci. 2018;63:746-754.
40.
Rueda-GotorJGonzález-GayMABlanco AlonsoRGonzalez-VelaCLopez-ObregonCGonzález-LópezMA.Successful effect of tocilizumab in anti-TNF-α-induced palmoplantar pustulosis in rheumatoid arthritis. Joint Bone Spine. 2012;79:510-513.
41.
JayasekeraPParslewRAl-SharqiA.A case of tumour necrosis factor-α inhibitor- and rituximab-induced plantar pustular psoriasis that completely resolved with tocilizumab. Br J Dermatol. 2014;171:1546-1549.
42.
GoodmanWALevineADMassariJVSugiyamaHMcCormickTSCooperKD.IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol. 2009;183:3170-3176.
43.
GaladariISheriffMO.Estimation of interleukin-6 level in psoriasis patients. Eur Ann Allergy Clin Immunol. 2005;37:63-65.
44.
SparsaLAfifNBularcaS, et al. Réactions cutanées paradoxales sous traitement par tocilizumab. La Revue De Médecine Interne. 2014;35:613-616.
45.
WendlingDGyselinckHLGuillotXPratiC.Psoriasis onset with tocilizumab treatment for rheumatoid arthritis: Figure 1. J Rheumatol. 2012;39:657.
46.
LaurentSLe ParcJMClériciTBrébanMMahéE.Onset of psoriasis following treatment with tocilizumab. Br J Dermatol. 2010;163:1364-1365.
47.
PearsonCMKlineHMNewcomerVD.Relapsing polychondritis. N Engl J Med. 1960;263:51-58.
48.
KwonWJKimMSParkJY, et al. A case of relapsing polychondritis with palmoplantar pustulosis. Indian J Dermatol. 2016;61:693-694.
49.
ComarmondCChimonASalfrantMSèneD.Relapsing polychondritis with palmoplantar pustulosis. J Rheumatol. Published online June 15, 2023. doi:10.3899/jrheum.2023-0003
50.
CaoXZhaoJXuDHouYZengX.Clinical characteristics of seven relapsing polychondritis cases misdiagnosed as arthritis. Ann Rheum Dis. 2019;78:574-575.
51.
HagerMHMooreME.Relapsing polychondritis syndrome associated with pustular psoriasis, spondylitis and arthritis mutilans. J Rheumatol. 1987;14:162-164.
52.
SongQWangZ.Relapsing polychondritis associated with pustular psoriasis successfully treated with secukinumab: a case-based review. Egypt Rheumatol Rehabil. 2024;51:35.
53.
BorbujoJBalsaAAguadoPCasadoM.Relapsing polychondritis associated with psoriasis vulgaris. J Am Acad Dermatol. 1989;20:130-132.
54.
MatsuoHAsahinaAFukudaTUmezawaYNakagawaH.Relapsing polychondritis associated with psoriasis vulgaris successfully treated with adalimumab: a case report with published work review. J Dermatol. 2017;44:826-829.
55.
MuraoKHidaYMinatoMKuboYAraseS.Relapsing polychondritis associated with psoriasis vulgaris and alopecia areata. Eur J Dermatol. 2011;21:779-780.
56.
HorinoTIchiiOMatsumotoTTeradaY.Relapsing polychondritis associated with psoriasis vulgaris. J Clin Rheumatol. 2019;27:S579-S580.
57.
LeeHCTsaiTF.Relapsing polychondritis-like ear disease responding to etanercept in two patients with psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2011;64:1006-1007.
